

ORCA Therapeutics invited to present on CMC and clinical development of ORCA-010 at the Gene and Cell Therapies: CMC, CGT & Vector Manufacturing + Aseptic Processing Summit

‘s-Hertogenbosch, the Netherlands, 17 November, 2021.

ORCA Therapeutics B.V., a clinical-stage biopharmaceutical company developing oncolytic immunotherapy to treat cancer was invited to present their proprietary CMC production platform and clinical study results at the Gene and Cell Therapies: CMC, CGT & Vector Manufacturing + Aseptic Processing Summit held in Munich (DE) from November 18 to November 19.

At the summit ORCA will provide an update on the development of ORCA’s enhanced oncolytic immunotherapy platform, our proprietary scalable production platform and the ongoing phase I/II clinical trial. ORCA’s lead compound, ORCA-010, is an enhanced oncolytic adenovirus designed for optimal safety, anti-cancer properties and synergy with standard of care cancer therapies or other therapeutics.

ORCA’s phase I clinical trial in patients with localized prostate cancer who have received no prior treatment was recently concluded and demonstrated excellent safety at all dose levels, with only grade I and grade II adverse events observed. Virus replication is evident as demonstrated by increased levels of shedding analysis in urine. Interim MRI analysis at 6 months post treatment demonstrated that patients with significantly enlarged prostates observed a reduction of prostate volume post treatment.

Meet our team in Munich to learn more about ORCA’s enhanced oncolytic immunotherapy platform, our proprietary scalable production platform and the ongoing phase I/II clinical trial.

For more information please visit <http://www.orca-therapeutics.nl/>

Please contact

Kees Groen, PhD., CEO
ORCA Therapeutics B.V.
+31